TGTX
TG Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$55.85
−1.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 799.5M | 616.3M | 329.0M | 233.7M | 2.8M |
| Cost of Revenue | 141.0M | 100.7M | 38.5M | 14.1M | 265.0K |
| Gross Profit | 658.5M | 515.6M | 290.5M | 219.5M | 2.5M |
| Operating Expenses | |||||
| R&D Expense | 225.8M | 160.2M | 94.3M | 76.2M | 125.4M |
| SG&A Expense | 296.4M | 232.0M | 154.3M | 122.7M | 95.5M |
| General & Admin Expense | 296.4M | 232.0M | 154.3M | 122.7M | 95.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 522.2M | 392.2M | 248.6M | 198.9M | 220.8M |
| Cost and Expenses | 663.2M | 493.0M | 287.1M | 213.0M | 221.1M |
| Operating Income (EBIT) | 136.3M | 123.3M | 41.9M | 20.6M | (218.3M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 37.5M | 26.7M | 24.0M | 12.6M | 10.2M |
| Net Interest Income | (37.5M) | (26.7M) | (24.0M) | (12.6M) | (10.2M) |
| Other Non-Op Income/Expense | (34.7M) | (15.9M) | (16.3M) | (7.6M) | (5.5M) |
| Non-Operating Income (excl Interest) | 2.4M | (10.8M) | (7.7M) | (5.0M) | (4.7M) |
| EBT (Pre-Tax Income) | 101.6M | 107.4M | 25.6M | 13.1M | (223.8M) |
| Income Tax Expense | (339.9M) | (339.8M) | 2.2M | 390.0K | — |
| Bottom Line | |||||
| Net Income | 441.5M | 447.2M | 23.4M | 12.7M | (223.8M) |
| Earnings from Cont. Ops | 441.5M | 447.2M | 23.4M | 12.7M | (223.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 441.5M | 447.2M | 23.4M | 12.7M | (223.8M) |
| Per Share | |||||
| Basic EPS | $3.04 | $3.10 | $0.16 | $0.09 | ($1.46) |
| Diluted EPS | $2.74 | $2.77 | $0.15 | $0.09 | ($1.46) |
| Revenue Per Share | $5.64 | $4.27 | $2.26 | $1.65 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 141.8M | 144.3M | 145.3M | 142.0M | 135.4M |
| Diluted Shares Outstanding | 157.3M | 161.4M | 160.3M | 148.5M | 135.4M |
| Profitability Metrics | |||||
| EBITDA | 134.2M | 134.4M | 49.9M | 26.1M | (213.1M) |
| D&A | 209.0K | 244.0K | 280.0K | 423.0K | 515.0K |
| EBIT | 134.0M | 134.1M | 49.6M | 25.7M | (213.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026